Phase 2 N=360 Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder
Insomnia Disorder
Primary: Change in Wake After Sleep Onset (WASO) From Baseline to Days 1 and 2 — -28.4; -32.3; -37.7; -47.1 minutes — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=23 Halifax PrenaBelt Trial
Sleep · Pregnancy · Stillbirth
Primary: Percentage (%) of Sleep Time Supine — 3.5; 16.4 percentage of sleep time (%)
N/A N=189,426 Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin
Diabetes Mellitus, Type 2
Primary: Number of Participants With Major Adverse Cardiovascular Event — 165; 151; 120; 102 Participants
N/A N=20 The Use of an "Anal-Tape" in Patients With Fecal Incontinence
Fecal Incontinence
Primary: Any Improvment in the Fecal Incontince Quality of Life Scale (FIQoLs) — 2.8; 3.3; 1.9; 2.5 score on a scale
Phase 4 N=30 Transepicardial With Transseptal Autologous CD 133+ Bone Marrow Cell Implantation in Patient Following CABG Surgery
Coronary Artery Disease
Primary: Myocardial Defect Perfusion — 15.76; 15.38; 2.08; 3.85 Percentage of Myocardial Perfusion
N/A N=90 A Study to Evaluate Effectiveness and Safety of Hyaluronic Acid (HA) Fillers
Volume Deficiency of the Midface
Primary: Percentage of Participants With Aesthetic Improvement of Midface — 96.8; 100; 97.1 percentage of participants
N/A N=200 Ghana PrenaBelt Trial: A Positional Therapy Device to Reduce Still-Birth
Sleep · Pregnancy · Stillbirth
Primary: Birthweight of Baby — 3186; 3079 grams
N/A N=312 Stepped Telemental Health Care Intervention for Depression
Depression
Primary: Depression — 10.51; 11.22; 7.84; 7.71 units on a scale
N/A N=95 Validation of a Food Frequency Questionnaire
Nutrition
Primary: Validated Food Frequency Questionnaire — 0.39; 0.35; 0.28; 0.32 Pearson correlation
Phase 4 N=379 Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose
Primary Open Angle Glaucoma · Ocular Hypertension
Primary: Safety With Respect to the Assessment of Conjunctival Hyperaemia in the Worse Eye — 4; 1; 5; 29 Participants — p=<0.0001
N/A N=30 ClearUP Longitudinal Pilot Study
Sinus Pain · Congestion
Primary: Numeric Rating Scale for Pain — 6.5; 3.6 score on a scale
N/A N=30 Obesity - Inflammation - Metabolic Disease: Effect of Lactobacillus Casei Shirota
Metabolic Syndrome
Primary: Change of Neutrophil Phagocytosis From Baseline to 3 Months — 0.06; 3.48 percentage of monocytes and granulocytes
Phase 1 N=16 Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/Emtricitabine
HIV Infections
Primary: Period 1: Area Under the Plasma Concentration-time Curve From Time 0 to the End of the Dosing Interval at Steady State (AUC [0-tau]) of TAF — 250.4 Hours*nanogram per…
N/A N=93 Rapid Flu Tests in Travelers With Fever
Influenza
Primary: Cost for the Medical Management of Patients — 581; 661 USD
Phase 2 N=87 Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Smallpox
Primary: Number of Participants With SAEs — 0; 0; 2; 0 Participants